CSIMarket
 


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 

Integrated Biopharma Inc's Tangible Leverage Ratio

INBP's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




INBP Tangible Leverage Ratio (Sep 30 2022)
I. Quarter
(Jun 30 2022)
IV. Quarter
(Mar 31 2022)
III. Quarter
(Dec 31 2021)
II. Quarter
(Sep 30 2021)
I. Quarter
Y / Y Tangible Equity Change 25.05 % 29.59 % 74.12 % 90.56 % 109.26 %
Y / Y Total Liabilities Change -18.02 % -39.9 % -34.55 % -34.63 % -46.07 %
Tangible Leverage Ratio MRQ 0.42 0.36 0.63 0.68 0.63
Overall Ranking # 1000 # 0 # 0 # 193 # 1041
Seq. Tangible Equity Change 0.25 % 9.43 % 5.63 % 7.92 % 3.89 %
Seq. Total Liabilities Change 16 % -37.74 % -2.54 % 16.47 % -14.96 %



Tangible Leverage Ratio first quarter 2022 Comment
Due to net new borrowings of 16%, Tangible Leverage Ratio detoriated to 0.42, below company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the first quarter 2022, 256 other companies have achieved lower Tangible Leverage Ratio than Integrated Biopharma Inc. While Tangible Leverage Ratio total ranking has deteriorated compare to the previous quarter from 0 to 1000.

Explain Tangible Leverage Ratio?
What is INBP Market Share?
Tangible Leverage Ratio first quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 257
Healthcare Sector # 472
Overall Market # 1000


Tangible Leverage Ratio Statistics
High Average Low
100.15 11.86 0.36
(Sep 30 2018)   (Jun 30 2022)




Financial Statements
Integrated Biopharma Inc's Tangible Equity $ 19 Millions Visit INBP's Balance sheet
Integrated Biopharma Inc's Total Liabilities $ 8 Millions Visit INBP's Balance sheet
Source of INBP's Sales Visit INBP's Sales by Geography


Cumulative Integrated Biopharma Inc's Tangible Leverage Ratio

INBP's Tangible Leverage Ratio for the trailling 12 Months

INBP Tangible Leverage Ratio

(Sep 30 2022)
I. Quarter
(Jun 30 2022)
IV. Quarter
(Mar 31 2022)
III. Quarter
(Dec 31 2021)
II. Quarter
(Sep 30 2021)
I. Quarter
Y / Y Tangible Equity TTM Growth 25.05 % 29.59 % 74.12 % 90.56 % 109.26 %
Y / Y Total Liabilities TTM Growth -18.02 % -39.9 % -34.55 % -34.63 % -46.07 %
Tangible Leverage Ratio TTM 0.51 0.57 0.68 0.87 1.13
Total Ranking TTM # 1040 # 1256 # 1508 # 1733 # 1822
Seq. Tangible Equity TTM Growth 0.25 % 9.43 % 5.63 % 7.92 % 3.89 %
Seq. Total Liabilities TTM Growth 16 % -37.74 % -2.54 % 16.47 % -14.96 %


TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Despite of the net new borrowings of 16% Integrated Biopharma Inc managed to decrease Tangible Leverage Ratio in I. Quarter to 0.51, above Integrated Biopharma Inc's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 70 other companies have achieved lower Tangible Leverage Ratio than Integrated Biopharma Inc. While Tangible Leverage Ratio total ranking has improved so far to 1038, from total ranking in previous quarter at 1267.

Explain Tangible Leverage Ratio?
What is INBP Market Share?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 204
Within the Market # 1039


TTM Tangible Leverage Ratio Statistics
High Average Low
0.97 0.34 0.04
(Jun 30 2019)   (Sep 30 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Tangible Equity
Lifevantage Corp  1.14 $ 35.710  Millions$ 31.336  Millions
Marinus Pharmaceuticals Inc   1.14 $ 93.338  Millions$ 82.004  Millions
Sonoma Pharmaceuticals Inc  1.13 $ 7.941  Millions$ 7.021  Millions
Sigilon Therapeutics Inc   1.13 $ 50.208  Millions$ 44.410  Millions
Geron Corp  1.11 $ 120.608  Millions$ 108.172  Millions
Royalty Pharma Plc  1.11 $ 11,520.505  Millions$ 10,416.403  Millions
Selecta Biosciences Inc  1.10 $ 93.358  Millions$ 84.907  Millions
Nektar Therapeutics  1.10 $ 368.783  Millions$ 335.722  Millions
Alaunos Therapeutics Inc   1.10 $ 35.231  Millions$ 32.113  Millions
Durect Corp  1.09 $ 31.285  Millions$ 28.685  Millions
Tg Therapeutics inc   1.07 $ 106.828  Millions$ 99.682  Millions
Oncorus Inc   1.05 $ 84.369  Millions$ 79.996  Millions
Accustem Sciences Inc   1.03 $ 0.825  Millions$ 0.798  Millions
Immunogen inc   1.02 $ 180.792  Millions$ 178.007  Millions
Otonomy Inc   1.02 $ 21.719  Millions$ 21.397  Millions
Aptevo Therapeutics Inc   1.01 $ 15.933  Millions$ 15.762  Millions
Arcus Biosciences Inc   0.99 $ 695.121  Millions$ 698.701  Millions
Spero Therapeutics Inc   0.98 $ 31.992  Millions$ 32.484  Millions
F star Therapeutics Inc   0.97 $ 25.953  Millions$ 26.622  Millions
Dynavax Technologies Corporation  0.93 $ 465.634  Millions$ 498.741  Millions
Bioxcel Therapeutics Inc   0.93 $ 117.832  Millions$ 126.986  Millions
Opiant Pharmaceuticals Inc   0.91 $ 18.695  Millions$ 20.491  Millions
Dar Bioscience Inc   0.91 $ 24.033  Millions$ 26.344  Millions
Nrx Pharmaceuticals Inc   0.91 $ 15.277  Millions$ 16.782  Millions
Arcutis Biotherapeutics Inc   0.90 $ 238.140  Millions$ 263.399  Millions
Alkermes Plc   0.89 $ 803.314  Millions$ 903.136  Millions
Nabriva Therapeutics Plc  0.88 $ 22.617  Millions$ 25.616  Millions
Corbus Pharmaceuticals Holdings Inc   0.88 $ 36.739  Millions$ 41.946  Millions
Ibio inc   0.85 $ 36.196  Millions$ 42.355  Millions
Zymeworks Inc   0.85 $ 120.505  Millions$ 141.093  Millions

Date modified: 2022-11-12T18:56:46+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DHCC's Profile

Stock Price

DHCC's Financials

Business Description

Fundamentals

Charts & Quotes

DHCC's News

Suppliers

DHCC's Competitors

Customers & Markets

Economic Indicators

DHCC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071